Skip to main content

99%+ HPLC Pure | Batch-Specific Third-Party COAs | Free Shipping Over $250

Menu

Kynetide Research Team | yesterday

Hims & Hers Enters the Peptide Market: What It Means for Research Peptide Buyers

A major telehealth brand just signaled that peptides are going mainstream. Here's what Hims & Hers' 2026 peptide launch means for the research community and quality-focused buyers.

A Telehealth Giant Bets on Peptides

Hims & Hers Health, the direct-to-consumer telehealth company best known for weight-loss and hair-loss treatments, says it plans to begin offering compounded peptides by the end of 2026. Executives have named sermorelin, glutathione, and NAD+ among the first products in the pipeline, with more peptides expected to follow as FDA rulemaking progresses. The announcement follows an FDA advisory panel's vote earlier this year recommending looser restrictions on six peptides that, until now, have circulated mainly as compounds sold for research purposes.

Why This Is a Big Deal

Analysts have pegged the addressable peptide market in the billions of dollars, and Hims & Hers itself has cited figures in that range when discussing its growth plans. A mainstream, publicly traded telehealth brand moving into this space signals that peptides are shifting from a niche research and biohacking interest into a category that large consumer health companies see as durable, credible demand rather than a passing trend.

What's Still Unsettled

Nothing is final yet. The FDA's advisory panel vote is a recommendation, not a rule, and the agency still needs to finalize its position on which peptides can be compounded and dispensed and under what conditions. Wall Street's reaction to the Hims & Hers announcement has been mixed, with some analysts questioning near-term revenue impact. It's also worth remembering that "research use only" peptides, the category most research suppliers operate in, remain legally and regulatorily distinct from any compounded, clinically dispensed products a telehealth company might eventually offer.

What It Means for Research Peptide Buyers

As mainstream players enter the space, quality and traceability matter more than ever. Growing consumer attention tends to attract more suppliers, not all of whom prioritize accurate labeling or third-party testing. Whether you're a lab, a researcher, or simply following the space closely, this is a good moment to double-check that any peptides you source come with a current Certificate of Analysis (COA) and a supplier that stands behind its purity claims. You can review our own lab reports and COAs, along with more sourcing guidance, on our resources page.

Let’s create what matters — together.

Kynetide Research Team

More Posts

Stanford Researchers on the Peptide Craze: Why Sourcing Is the Real RiskStanford Researchers on the Peptide Craze: Why Sourcing Is the Real Risk
Stanford Researchers on the Peptide Craze: Why Sourcing Is the Real Risk

Peptides are everywhere in wellness culture right now, promoted for everything from muscle building to weight loss to smoother skin. But Stanford Medicine researchers say the excitement has outpaced the evidence. In a recent breakdown of the trend, pathology professors Katrin Svensson and Jonathan Long laid out what's actually known, what isn't, and why the biggest danger for most people isn't the peptide itself. It's where it came from.

Aug 15 | Kynetide Research Team
Understanding Research Peptide Purity: How to Read a COA and Verify QualityUnderstanding Research Peptide Purity: How to Read a COA and Verify Quality
Understanding Research Peptide Purity: How to Read a COA and Verify Quality

When you're purchasing research peptides, one number matters most: purity. But what does "99.1% pure" actually mean? And how do you know a certificate of analysis (COA) is legitimate? In this guide, we'll walk you through peptide quality standards, how purity is measured, and what red flags to watch for when sourcing research-grade compounds.

Aug 14 | Kynetide Research Team
WVU Pharmacy Experts Weigh In on the Peptide Boom: Why "Real Data" Still WinsWVU Pharmacy Experts Weigh In on the Peptide Boom: Why "Real Data" Still Wins
WVU Pharmacy Experts Weigh In on the Peptide Boom: Why "Real Data" Still Wins

A 2026 market-news look at West Virginia University pharmacy experts' call for stronger evidence behind the multibillion-dollar peptide industry, and why third-party-verified sourcing matters most for anyone doing research today.

Aug 13 | Kynetide Research Team
BPC-157 in 2026: Why Purity and Testing Standards Matter More Than EverBPC-157 in 2026: Why Purity and Testing Standards Matter More Than Ever
BPC-157 in 2026: Why Purity and Testing Standards Matter More Than Ever

BPC-157 remains one of the most discussed compounds in the peptide research community, but interest in it has outpaced the published science. Here's what the current evidence actually shows, and why purity and testing matter more for this peptide than most.

Aug 12 | Kynetide Research Team
New Real-World Study Links Tirzepatide to Fewer Heart Attacks in Type 2 DiabetesNew Real-World Study Links Tirzepatide to Fewer Heart Attacks in Type 2 Diabetes
New Real-World Study Links Tirzepatide to Fewer Heart Attacks in Type 2 Diabetes

Tirzepatide is best known for its glucose- and weight-lowering effects, but a newly published study adds evidence for another benefit: a real reduction in serious cardiovascular events. Published in The British Medical Journal, it's one of the largest real-world looks yet at how tirzepatide performs on cardiovascular outcomes outside a clinical trial setting.

Aug 10 | Kynetide Research Team
Rice Engineers Find a Way to Make Peptides Stay Put Longer in Gelatin Delivery SystemsRice Engineers Find a Way to Make Peptides Stay Put Longer in Gelatin Delivery Systems
Rice Engineers Find a Way to Make Peptides Stay Put Longer in Gelatin Delivery Systems

Peptides are prized for their ability to drive specific biological processes like bone formation and tissue repair, but their small size has always worked against them in drug delivery: once placed in water-rich materials like hydrogels, they tend to diffuse away long before healing is complete. A new Rice University study, published in Cell Biomaterials, offers a surprisingly simple fix.

Aug 9 | Kynetide Research Team
A Harvard Medical Perspective on the Peptide BoomA Harvard Medical Perspective on the Peptide Boom
A Harvard Medical Perspective on the Peptide Boom

Harvard Health Publishing recently examined the fast-growing world of injectable peptides, from FDA-approved medications like insulin and GLP-1 drugs to the unregulated compounds sold online for research and personal use. Their findings offer a useful checkpoint for anyone following the peptide space, including everyone in our own research community.

Aug 7 | Kynetide Research Team
A New Accreditation Body Wants to Standardize Peptide Quality — Here's What It Means for ResearchersA New Accreditation Body Wants to Standardize Peptide Quality — Here's What It Means for Researchers
A New Accreditation Body Wants to Standardize Peptide Quality — Here's What It Means for Researchers

A new nonprofit is building the first peptide-specific accreditation standards for compounding and sourcing, just as regulators weigh whether to expand access to several popular research peptides.

Aug 5 | Kynetide Research Team
Inside the Peptide Controversy: Why FDA Scientists and Critics Are Pushing BackInside the Peptide Controversy: Why FDA Scientists and Critics Are Pushing Back
Inside the Peptide Controversy: Why FDA Scientists and Critics Are Pushing Back

The FDA advisory panel's vote to ease restrictions on six peptides made headlines this week. But the vote wasn't as clear-cut as the headlines suggest. Behind the scenes, FDA's own scientific staff recommended against it, several panel members have documented industry ties, and the peptides in question are already circulating on the unregulated gray market. Here's what the coverage is missing.

Aug 5 | Kynetide Research Team